Echoing Pfizer, OSI To Put IGF-1R Candidate In Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to piggyback the potential lung-cancer drug – combined with Tarceva – on current Phase I study, as investors await SATURN and ATLAS details at ASCO.